Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Delgaizo

Adult Reconstructive Orthopaedic Surgery Beaufort, SC Medical Doctor

NPI 1205057577 CMS profile 235309

1076 Ribaut Rd Ste 101, Beaufort, SC 29902

Open in the dashboard

General payments

$25,413

90 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$192,103 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Daniel Delgaizo of Beaufort, SC is reported in the CMS Open Payments database as having received $25,413 across 90 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $192,103 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,070 7
2024 General $11,918 11
2023 General $1,001 7
2022 General $2,270 17
2021 General $3,641 24
2020 General $2,494 18
2019 General $1,020 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Delgaizo
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Daniel Delgaizo were reported at $3,070. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Daniel Delgaizo Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $1,020 $1,416 $292–$9,336 $163
2020 $2,494 $647 $141–$6,474 $114
2021 $3,641 $1,073 $211–$6,497 $132
2022 $2,270 $1,217 $236–$6,299 $149
2023 $1,001 $1,082 $246–$6,818 $160
2024 $11,918 $1,575 $323–$8,944 $164
2025 $3,070 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $14,350 10 payments
  2. Zimmer Biomet Holdings, Inc. $3,339 22 payments
  3. Medacta USA, Inc. $2,996 21 payments
  4. Stryker Corporation $1,781 11 payments
  5. DePuy Synthes Sales Inc. $1,013 9 payments
  6. Orthalign Inc $750 1 payment
  7. SPR Therapeutics, Inc $338 1 payment
  8. Conformis, Inc. $270 5 payments
  9. Smith+Nephew, Inc. $212 4 payments
  10. Osteoremedies, LLC $150 1 payment
  11. Other $215 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,992 7 payments
  2. Travel and Lodging $6,266 28 payments
  3. Food and Beverage $4,156 55 payments
Products named General payments · program years 2019–2025
  1. ATTUNE $14,374 7 payments
  2. Persona Revision $2,322 12 payments
  3. AMISTEM $2,229 16 payments
  4. MAKO $1,781 11 payments
  5. OrthAlign Plus System $750 1 payment
  6. GMK SPHERE $521 2 payments
  7. SPRINT PNS System $338 1 payment
  8. Persona $309 3 payments
  9. Hip $261 4 payments
  10. Avenir $233 2 payments
  11. Other $2,096 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

804

Median for Orthopedic Surgery: 203

Drug cost

$3,253

Median for Orthopedic Surgery: $1,433

Branded share of claims

14.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 114 $935
Oxycodone Hcl Generic 126 $814
Meloxicam Generic 274 $597
Tramadol Hcl Generic 179 $477
Cephalexin Generic 69 $157
Cyclobenzaprine Hcl Generic 20 $111
Diclofenac Sodium Generic 11 $92
Cefadroxil Generic 11 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$547,259

Of which drugs: $137,178

Medicare patients

1,016

Average age 75

Services billed

35,001

595 women, 421 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Diabetes 19%
Ischemic heart disease 18%
Chronic kidney disease 15%
Cancer 15%
Depression 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 150 177 $73,249
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 49 2,560 $35,383
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 53 3,900 $18,950
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 11 1,200 $6,720
Injection, methylprednisolone acetate, 1 mg J1010 Office 213 23,097 $2,333
Injection, methylprednisolone acetate, 80 mg J1040 Office 71 82 $545

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record